CTOR CITIUS ONCOLOGY, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1851484 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-73.3%
TTM EPS YoY-26.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-126.6%
ROA-45.2%
ROIC (approx.)-132.9%
Asset turnover—
Leverage & solvency
Liabilities / assets64.0%
Debt / equity0.00x
Current ratio0.73x
Interest coverage-128.56x
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-12-31 | FY20232023-09-30 | FY20222022-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $6.42M | $4.93M | — | $4.24M | — |
| SG&A expense | $8.78M | $8.15M | $1.01M | $5.92M | $138,115 |
| Operating income | -$23.52M | -$20.57M | -$1.01M | — | -$138,115 |
| Interest expense | $218,032 | — | — | — | — |
| Pretax income | -$23.70M | -$20.57M | — | -$12.12M | — |
| Income tax | $1.06M | $576,000 | — | $576,000 | — |
| Net income | -$24.76M | -$21.15M | $2.42M | -$12.70M | $380,811 |
| EPS (basic) | -0.34 | -0.31 | 0.27 | -0.19 | 0.12 |
| EPS (diluted) | -0.34 | -0.31 | 0.27 | -0.19 | 0.12 |
| Weighted avg. shares (diluted) | 73.27M | 68.05M | 6.60M | 67.50M | 1.34M |
| Balance sheet | |||||
| Cash & equivalents | $3.92M | $112 | $32,746 | $26,523 | $289,175 |
| Inventory | $22.29M | $8.27M | — | — | — |
| Current assets | $27.54M | $10.97M | $58,200 | $7.73M | $377,344 |
| Total assets | $100.94M | $84.37M | $72.62M | $47.73M | $68.19M |
| Current liabilities | $49.49M | $32.70M | $2.05M | $21.05M | $31,836 |
| Total liabilities | $56.08M | $38.23M | -$22.67M | $22.20M | $31,836 |
| Shareholders' equity | $44.87M | $46.14M | $22.73M | $25.54M | $345,508 |
| Shares outstanding | 83.51M | 71.55M | 2.34M | 67.50M | 2.42M |
| Cash flow statement | |||||
| Operating cash flow | -$5.49M | $126,353 | -$601,304 | — | -$47,968 |
| Investing cash flow | -$5.75M | -$5.00M | -$1.32M | — | -$67.32M |
| Financing cash flow | $15.17M | $4.87M | $1.66M | — | $67.66M |
| Stock-based compensation | $8.32M | $7.50M | — | $1.97M | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.